The optimal strategy for glycemic control in elderly adults with diabetes is uncertain because of competing risks from non-diabetic conditions and higher risk of adverse drug effects. The lack of specificity in current treatment guidelines for elderly patients reflects the weak evidence base for decision-making. To quantify the implications of potential changes in treatment guidelines, we characterize current drug usage by diabetic elders in the US and quantify the number who might benefit from reduced anti-diabetic drug exposure if the target HbA1c were increased in the elderly.
75.0% had diagnosed hypertension, 62.4% had diagnosed high cholesterol; 46.7% had cardiovascular disease; 25.3% had a history of cancer; and 22.0% had retinopathy. Mean (±SE) HbA1c was 6.8% (±0.06): 63.4%, 23.9%, and 12.8% of diabetic elders had HbA1c under 7%, 7 -7.9%, and 8% or higher, respectively (see Figure) . More than 80% of elders were treated with anti-diabetic medications: 39.4% with sulfonylureas, 36.8% with metformin, 18.7% with thiazolidinediones (TZDs), and 17.3% with insulin. Most elders also used multiple non-diabetes prescription medications (52.3% used 4 or more; 31.0% used six or more) for a mean (±SE) of 5.4 (±0.2) for total number of prescription medications. Two percent of diabetic elders used metformin despite contraindications (renal dysfunction or age ≥ 80) (corresponding to 168,000 individuals) and 3.4% used a TZD despite a history of heart failure (corresponding to 286,000 individuals).
The Figure displays medication use by HbA1c level. 49.9% all elders (corresponding to the darker gray area) were on medications with an HbA1c less than 7%; in fact, 20.9% of all elders were on multiple medications in order to achieve this HbA1c level. If the glycemic target for diabetic elders were raised from 7% to 8%, then 49.9% (dark gray area in the Figure) of diabetic elders (3.2 million adults) might be able to discontinue or reduce their anti-diabetic medication regimen.
In addition to this group, 17.2% of diabetic elders (corresponding to the light gray area) who had HbA1c between 7 and 7.9% were taking medications other than metformin or taking more than one drug. These patients may also modify their anti-diabetic medications regimen. These patients would correspond to an additional 1.1 million elders.
DISCUSSION
About 81% of diabetic elders in the US use one or more anti-diabetic medication; about 60% of diabetic elders are taking anti-diabetic medications besides metformin; and about 5% are using an anti-diabetic drug despite an apparent contraindication to its use. In addition, most diabetic elders are taking 5 or more prescription medications in total.
The present level of prescribing for elderly diabetics is very likely a reflection of physicians pursuing the standard glycemic control HbA1c target of <7.0%. Although tighter glycemic control reduces microvascular risk 1 , hypoglycemia, polypharmacy, and other adverse drug effects pose special concerns for diabetic elders. Severe hypoglycemic episodes may contribute to dementia 2 ; polypharmacy may increase the risk of injurious falls 3, 4 . Moreover, In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the all-cause mortality in intensive versus standard glycemia group was not different among those participants age 65 or older 5 . A higher glycemic goal may be appropriate for elderly individuals, particularly those with severe or frequent hypoglycemia.
The 2011 American Diabetes Association Standards of Medical Care for Diabetes 6 recommends HbA1c < 7% for most individuals with diabetes, but qualifies the recommendation for older adults: "For patients with advanced diabetes complications, lifelimiting comorbid illness, or substantial cognitive or functional impairment, it is reasonable to set less-intensive glycemic target goals." Similarly, the 2003 American Geriatrics Society's Guidelines for Improving the Care of the Older Person with Diabetes Mellitus 7 recommends "For frail older adults, persons with life expectancy of less than 5 years, and others in whom the risks of intensive glycemic control appear to outweigh the benefits, a less stringent target such as 8% is appropriate."
The 2011 VA-DoD Diabetes Guidelines Working Group 8 recommends HbA1c targets based on shared decision making between clinicians and patients that focuses on life expectancy. Specific recommendations for HbA1c target ranges from < 7% to < 9% are offered based on age or the presence/severity of major comorbidities and microvascular complications. Although this individualized approach to diabetes care is clinically reasonable, there is no direct trial in an elderly population to support a target of 7% as opposed to 8% and no direct trial evidence supporting an individualized approach.
If the general HbA1c goal in diabetic elders were raised from 7% to 8%, more than 3 million diabetic adults in the US, might be able to simplify their diabetes care. Whether a higher HbA1c target is indeed appropriate will require a randomized controlled trial focused on diabetic elders. 
